trimetrexate has been researched along with Acute Myelogenous Leukemia in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kheradpour, A | 1 |
| Berman, E | 1 |
| Göker, E | 1 |
| Lin, JT | 1 |
| Tong, WP | 1 |
| Bertino, JR | 1 |
1 trial available for trimetrexate and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia.
Topics: Adult; Aged; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Precursor Cell | 1995 |